Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin's lymphoma

Haematologica

Volumn 94, Issue 10, 2009, Pages 1456-1459

  Sapra, Puja ^a   Kraft, Patricia ^a   Mehlig, Mary ^a   Malaby, Jennifer ^a   Zhao, Hong ^a   Greenberger, Lee M ^a   Horak, Ivan D ^a  

^a Enzon Incorporated   (United States)

Author keywords

B cell non Hodgkin's lymphoma; CPT 11; Drug conjugate; In vivo; Polyethylene glycol; SN38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; EZN 2208; IRINOTECAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROGNOSIS; XENOGRAFT;

ANIMALS; BURKITT LYMPHOMA; CAMPTOTHECIN; CELL LINE, TUMOR; FEMALE; HUMANS; LYMPHOMA, B-CELL; MICE; MICE, SCID; POLYETHYLENE GLYCOLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70349645655     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.008276     Document Type: Article

References (17)

1. Peterson BA, Petroni GR, Frizzera G, Barcos M, Bloomfield CD, Nissen NI, et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the Cancer and Leukemia Group B. J Clin Oncol 2003;21:5-15.
2. Kimby E, Björkholm M, Gahrton G, Glimelius B, Hagberg H, Johansson B, et al. Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the lymphoma group of central Sweden. Ann Oncol 1994;5:67-71.
3. Leonard JP, Gregory SA, Maloney DG, Vose JM, Younes A, Zelenetz AD. Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma. Clin Adv Hematol Oncol 2008;6:437-445
4. Tobinai K, Hotta T, Saito H, Ohnishi K, Ohno R, Ogura M, et al. Combination phase I/II study of irinotecan hydrochloride (CPT-11) and carboplatin in relapsed or refractory non-Hodgkin's lymphoma. Jpn J Clin Oncol 1996;26:455-460 (Pubitemid 126471805)
5. Tsuda H, Takatsuki K, Ohno R, Masaoka T, Okada K, Shirakawa S, et al. Treatment of adult T-cell leukaemia- lymphoma with irinotecan hydrochloride (CPT-11). Br J Cancer 1994;70:771-774 (Pubitemid 24305620)
6. Niitsu N, Iijima K, Chizuka A. Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin's lymphoma: a pilot study. Ann Hematol 2001;80:411-416 (Pubitemid 32725459)
7. Sugiyama K, Omachi K, Fujiwara K, Saotome T, Mizunuma N, Takahashi S, et al. Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin's lymphoma: a single institution experience. Cancer 2002;94:594-600. (Pubitemid 34132285)
8. Sarris AH, Phan A, Goy A, Romaguera J, Hagemeister FB, Rodriguez MA, et al. Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial. Oncology 2002;16: 27-31.
9. Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 1997;33:245-59.
10. Zhao H, Rubio B, Sapra P, Wu D, Reddy P, Sai P, et al. Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers. Bioconjug Chem 2008;19:849-859
11. Sapra P, Zhao H, Mehlig M, Malaby J, Kraft P, Longley C, et al. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clin Cancer Res 2008;14:1888-1896
12. Sapra P, Kraft P, Mehlig M, Malaby J, Castaneda S, Greenberger LM, et al. A novel polyethyleneglycol-SN38 conjugate, EZN-2208, downregulates HIF-1α and results in significant tumor growth inhibition in K-ras mutant cancer xenograft models. Abstract n. LB-39, 2009 Annual Meeting of American Association for Cancer Research.
13. Rapisarda A, Zalek J, Hollingshead M, Braunschweig T, Uranchimeg B, Bonomi CA, et al. Schedule-dependent inhibition of hypoxia-inducible factor-1a protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 2004; 64:6845-6848 (Pubitemid 39330988)
14. Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor- 1: mechanism and therapeutic implications. Cancer Res 2004;64: 1475-1482 (Pubitemid 38235619)
15. Evens AM, Schumacker PT, Helenowski IB, Singh AT, Dokic D, Keswani A, et al. Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin family. Br J Haematol 2008;141:676-680 (Pubitemid 351667626)
16. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1a and vascular endothelial growth factor formation. Mol Cancer Ther 2003;2:235-243
17. Guo Z, Wheler J, Naing A, Mani S, Goel S, Mulcahy M, et al. Clinical pharmacokinetics (PK) of EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies: a phase I, first-in-human, dose-escalation study. J Clin Oncol 2008;26(20 suppl):2556. (Abstract)